Phosphagenics Initiates US Clinical Trial for Dermatological Product
Posted on: Wednesday, 20 February 2008, 12:02 CST
Biotechnology firm Phosphagenics has initiated a human clinical trial for its lead dermatological product, retinoic acid, a form of vitamin A.
This trial is claimed to be the company's first clinical trial to take place in the US and denotes the commencement of the company's planned expansion into targeted, non-systemic delivery of drugs. According to the American Journal of Dermatology, retinoic acid is prescribed most often as the topical treatment of choice for acne.
Harry Rosen, president & CEO of Phosphagenics, said: "A new formulation with the ability to deliver greater absorption of retinoic acid, reduce irritation and dryness and limit systemic circulation would significantly increase practitioners' flexibility in prescribing the product. It would enable physicians to prescribe greater doses of retinoic acid and/or maintain current dosing while achieving improved efficacy and substantially limiting adverse effects."
Source: Datamonitor
Related Articles
- Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase I Clinical Trial of PXD101 and Cis-Retinoic Acid
- Preliminary Trials Completed Using VSEP Vibratory Membrane Filtration for Treatment of Acidic Wastewater From Phosphate Ore Processing
- Pulp Mill Reduces Dirt Counts With Brownstock Acidification
- Retinoic Acid Supplementation Attenuates Ventricular Remodeling After Myocardial Infarction in Rats1-3
- Folic Acid May Delay Decline in Thinking Skills; Studies Suggest Promising Therapies for Alzheimer's
- Study Compares Stomach Acid Control of Three Proton Pump Inhibitors in Chronic NSAID Users
- Inovio Biomedical and University of Southampton Collaboration: Initiation of Phase I/II Clinical Trial in Patients With Recurrent Prostate Cancer
- Establishment and Characterization of Cell Lines From 3 Human Thyroid Carcinomas: Responses to All-Trans-Retinoic Acid and Mutations in the BRAF Gene
 |
 |
User Comments (0)
RSS Feeds